Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Apr;19(105):275-84.

New approaches for the immunotherapy of acute myeloid leukemia

Terrence L Geiger  1 , Jeffrey E Rubnitz  2
Affiliations
Review

New approaches for the immunotherapy of acute myeloid leukemia

Terrence L Geiger et al. Discov Med. 2015 Apr.

Abstract

Acute myeloid leukemia (AML) is a set of related diseases characterized by the immortalization and uncontrolled expansion of myeloid precursor cells. Core therapy for AML has remained unchanged for nearly 30 years, and survival rates remain unsatisfactory. However, advances in the immunotherapy of AML have created opportunities for improved outcomes. Enforcing a tumor-specific immune response through the re-direction of the adaptive immune system, which links remarkable specificity with potent cytotoxic effector functions, has proven particularly compelling. This may be coupled with immune checkpoint blockade and conventional therapies for optimal effect. Engineered antibodies are currently in use in AML and the repertoire of available therapeutics will expand. NK cells have shown effectiveness in this disease. New methods to optimize their activation and the targeting of AML show potential. Most significantly, adoptive immunotherapy with tumor-specific T cells, and particularly T cells re-directed using genetically introduced TCR or chimeric antigen receptors, have demonstrated promise. Each of these approaches has unique benefits and challenges that we explore in this review.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Adoptive immunotherapy of AML
Depiction of methods to target AML, including: (A) Infusion of AML-antigen-specific cytolytic T lymphocytes. These can be generated through the in vitro expansion of tumor antigen-specific lines or transduction of T cells with tumor-specific TCR; (B) Infusion of tumor antigen-specific CD4+ T cells. These may promote direct tumor lysis or act through their ability to support CD8+ T cell expansion and memory; (C) transfer of CAR-modified CD8+ T cells re-directed through a scFv-TCR hybrid specific for lineage or tumor antigens expressed by AML blasts; (D) infusion of AML-specific antibodies modified to enhance their cytolytic potential through conjugated therapeutics; (E) transfer of NK cells that are activated and target AML in response to FcR binding, AML-specific antibodies or other activating receptors. NK cells can be infused fresh after collection or activated and expanded in vitro; (F) transfer of NK cells modified to express activating CAR. Blue arrows indicate direction of helper activities, red arrows indicate cytotoxic activities.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Alli R, Zhang ZM, Nguyen P, Zheng JJ, Geiger TL. Rational design of T cell receptors with enhanced sensitivity for antigen. PLoS One. 2011;6(3):e18027. - PMC - PubMed
    1. Bachanova V, Cooley S, DeFor TE, Verneris MR, Zhang B, McKenna DH, Curtsinger J, Panoskaltsis-Mortari A, Lewis D, Hippen K, McGlave P, Weisdorf DJ, Blazar BR, Miller JS. Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. Blood. 2014;123(25):3855–3863. - PMC - PubMed
    1. Baker SD, Zimmerman EI, Wang YD, Orwick S, Zatechka DS, Buaboonnam J, Neale GA, Olsen SR, Enemark EJ, Shurtleff S, Rubnitz JE, Mullighan CG, Inaba H. Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia. Clin Cancer Res. 2013;19(20):5758–5768. - PMC - PubMed
    1. Berthon C, Driss V, Liu J, Kuranda K, Leleu X, Jouy N, Hetuin D, Quesnel B. In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors. Cancer Immunol Immunother. 2010;59(12):1839–1849. - PMC - PubMed
    1. Blankenstein T, Leisegang M, Uckert W, Schreiber H. Targeting cancer-specific mutations by T cell receptor gene therapy. Curr Opin Immunol. 2015;33C:112–119. - PMC - PubMed

Publication types

MeSH terms